ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

April 25th 2025, 1:00pm

By Ryan Scott

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

The Fearless Patient Advocate

April 24th 2025, 9:00pm

By Antonia Maloney, BSN, RN, OSN

Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”

Working to Address Unmet Medical Needs in MPNs

April 24th 2025, 8:00pm

By John Crispino

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

April 24th 2025, 7:00pm

By Spencer Feldman

The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

April 24th 2025, 5:00pm

By Jane Biehl Ph.D.

After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

April 24th 2025, 3:58pm

By Alex Biese

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

April 24th 2025, 3:00pm

By Ryan Scott

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.

Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer

April 24th 2025, 1:00pm

By Spencer Feldman

In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing research to improve patient outcomes.

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

April 23rd 2025, 9:00pm

By Alex Biese

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer

April 23rd 2025, 8:00pm

By Dr. Douglas Reznick

Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis.

Joy Anderson Reflects on Her Diagnosis of a Rare Blood Cancer

April 23rd 2025, 7:00pm

By Joy Anderson

A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed.

The Burst of Spring: Reflection for Those Living with Cancer

April 23rd 2025, 5:00pm

By Linda Cohen

As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop my treatment. Life is a gift.

Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression

April 23rd 2025, 4:00pm

By Alex Biese

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.

FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor

April 23rd 2025, 2:59pm

By Ryan Scott

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.

First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors

April 23rd 2025, 1:00pm

By Spencer Feldman